Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-07-23 EDT 5-day change 1st Jan Change
4,292.00 JPY +0.73% Intraday chart for Takeda Pharmaceutical Company Limited -0.14% +5.87%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Dr. Reddy's Laboratories to Market Takeda's Acid-Reflux Medication in India MT
Dr. Reddy's Laboratories Ltd. Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceutical Company Limited to Commercialise Vonoprazan Tablets in India CI
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading MT
Zydus Lifesciences Signs Licensing Pact to Market Vonoprazan in India MT
Takeda Issues New Shares, Disposes of Treasury Shares Under Incentive Scheme MT
Blackstone selling Japan drugmaker Alinamin to MBK Partners RE
Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan MT
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan CI
Codexis Sells Fabry, Pompe Disease Compounds to Crosswalk Therapeutics MT
Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited. CI
Takeda Announces Board and Committee Changes CI
Transcript : Takeda Pharmaceutical Company Limited - Shareholder/Analyst Call
US CDC alerts healthcare providers of increase in dengue cases RE
Takeda's Cancer Drug Gets European Commission Approval MT
Hutchmed China notes Takeda obtains EU approval for Fruzaqla AN
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators MT
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment MT
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare CI
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts MT
Takeda Receives European Commission Approval for Colorectal Cancer Treatment MT
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib) CI
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia CI
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla MT
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment DJ
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer CI
Chart Takeda Pharmaceutical Company Limited
More charts
Logo Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Employees
49,281
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,292.00JPY
Average target price
4,729.94JPY
Spread / Average Target
+10.20%
Consensus
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. News Takeda Pharmaceutical Company Limited
  5. Takeda Says Narcolepsy Drug Meets Main, Secondary Goals in Trial